Novartis Message Board - Msg: 13214802

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novartis

NVS 123.79

+1.0%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jack Hartmann who wrote (270)	3/16/2000 1:04:00 AM
From: Jack Hartmann	Read Replies (1) of 296

Novartis Unit, QLT Photothera Expand Visudyne Trial Dow Jones Newswires 3/15/2000 ATLANTA -- Novartis AG's (Z.NOV) Ciba Vision unit and QLT PhotoTherapeutics Inc. (QLTI) expanded their ongoing treatment-investigational new drug clinical program for Visudyne, a treatment for "wet" age-related macular degeneration. In a press release Wednesday, Ciba Vision said the program will provide Visudyne therapy at additional sites to patients who meet specific eligibility criteria. The program began in September 1999, with 200 sites. Under the T-IND filed March 15, the company will add up to 200 new sites. As reported, in February the companies received an approvable letter from the Food and Drug Administration for Visudyne and expected approval "shortly." FDA approval will help the lagging sector. Jack

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next